Nicox announces the presentation of NCX 667 scientific data at AOPT 2017

19:00 EST 20 Feb 2017 | Globe Newswire

Press Release

Nicox announces the presentation of NCX 667 scientific data at AOPT 2017  

New preclinical data demonstrate NCX 667's robust IOP lowering properties

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy. NCX 667, synthesized by Nicox, is the lead compound of a new class of next-generation stand-alone NO-donors, which are designed to optimize NO dosing and enable intraocular pressure (IOP) lowering in patients with open angle glaucoma (OAG) or ocular hypertension

The AOPT 2017 abstract by Impagnatiello et al1 presented preclinical results obtained with NCX 667 in rabbit and non-human primate models of ocular hypertension and glaucoma following single and repeated treatment schedules. NCX 667 appeared to lower IOP by 20% or more regardless of the specific model and animal species used. Furthermore, repeated acute dosing of NCX 667 elicits sustained IOP-lowering activity over time with no signs of tachyphylaxis or ocular discomfort.  

Data from a variety of experimental animal models coupled with recent clinical studies strongly support an important role of NO in lowering IOP by enhancing aqueous humor drainage via the conventional outflow route.

Open angle glaucoma is a common ocular disorder affecting about 2% of the adult population over 40 years old and is the second-leading cause of blindness worldwide. 

About NCX 667  

Developed by Nicox, NCX 667 already demonstrated promising preclinical results in two preclinical models of ocular hypertension and glaucoma. In both models, NCX 667 appeared well-tolerated and effective in reducing intra-ocular pressure (IOP). These results were selected by the ARVO 2015 Annual Meeting Program Committee as a 'Hot Topic', as representing the newest and most innovative research being conducted.  


  1. NCX 667, a lead nitric oxide (NO)-donating compound for a new class of ocular hypotensive agents   F. Impagnatiello1, E. Bastia1, N. Almirante1, C. Toris2, C. Lanzi3, E. Ongini1, E. Masini3, M.V.W Bergamini4   1Nicox Research Institute, Milan, Italy; 2Department of Ophthalmology, Case Western Reserve University, Cleveland, OH, USA; 3Department of NEUROFARBA, University of Florence, Florence, Italy; 4Nicox Ophthalmics, Inc., Fort Worth, TX, USA
  2. Glaucoma, Open-angle -, accessed February 13, 2017

About Nicox

Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health.   By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma.  Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications.  Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit:

Analyst coverage

Bryan, Garnier & Co   Hugo Solvet   Paris, France
Invest Securities   Martial Descoutures   Paris, France
Gilbert Dupont   Damien Choplain   Paris, France 
Stifel    Olivia Manser   London, UK

Upcoming financial and business conferences

March 6-8  Cowen and Company 37th Annual Health Care Conference  Boston, US
March 21-22  Oppenheimer 27th Annual Healthcare Conference  New York, US 
April 4-5  Needham's 16th Annual Healthcare Conference New York, US
May 30   Gilbert Dupont 15th Annual Helthcare Conference  Paris, France 
June 19-22  2017 BIO International Convention  San Diego, US

Gavin Spencer,
Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00
Investor Relations
Julien Perez, Valentine Brouchot
T +33 (0)1 44 71 94 94
Media Relations
United Kingdom
Jonathan Birt
T +44 7860 361 746
United States
Argot Partners 
Melissa Forst
T +1 (212) 600-1902
Nicolas Merigeau
T +33 (0)1 44 71 94 98
 United States
Argot Partners 
Eliza Schleifstein
T +1 (917) 763-8106


The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313,  Sophia Antipolis
06560 Valbonne,  France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99



More From BioPortfolio on "Nicox announces the presentation of NCX 667 scientific data at AOPT 2017"

Quick Search


Relevant Topics

Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...